IL111287A0 - Methods for treating resistant neoplasms - Google Patents

Methods for treating resistant neoplasms

Info

Publication number
IL111287A0
IL111287A0 IL11128794A IL11128794A IL111287A0 IL 111287 A0 IL111287 A0 IL 111287A0 IL 11128794 A IL11128794 A IL 11128794A IL 11128794 A IL11128794 A IL 11128794A IL 111287 A0 IL111287 A0 IL 111287A0
Authority
IL
Israel
Prior art keywords
chem
methods
treating resistant
resistant neoplasms
neoplasms
Prior art date
Application number
IL11128794A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL111287A0 publication Critical patent/IL111287A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
IL11128794A 1993-10-15 1994-10-13 Methods for treating resistant neoplasms IL111287A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13767893A 1993-10-15 1993-10-15

Publications (1)

Publication Number Publication Date
IL111287A0 true IL111287A0 (en) 1994-12-29

Family

ID=22478575

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11128794A IL111287A0 (en) 1993-10-15 1994-10-13 Methods for treating resistant neoplasms

Country Status (17)

Country Link
EP (1) EP0652004B1 (no)
JP (1) JPH07149638A (no)
KR (1) KR950010891A (no)
CN (1) CN1108094A (no)
AT (1) ATE220323T1 (no)
AU (1) AU670518B2 (no)
CA (1) CA2118096A1 (no)
CZ (1) CZ253694A3 (no)
DE (1) DE69430940T2 (no)
DK (1) DK0652004T3 (no)
ES (1) ES2179063T3 (no)
HU (1) HUT71237A (no)
IL (1) IL111287A0 (no)
NO (1) NO943874L (no)
PT (1) PT652004E (no)
RU (1) RU94037233A (no)
ZA (1) ZA948025B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441964A (en) * 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene
CZ51897A3 (en) * 1994-08-22 1997-06-11 Lilly Co Eli Inhibition method of endometrial cancer
DK0771201T3 (da) * 1994-08-22 2001-05-07 Lilly Co Eli Anvendelse af 2-phenyl-3-aroylbenzothiophener til fremstilling af et medikament til inhibering af primær endometrisk hyperplasi
WO1996006604A2 (en) * 1994-08-31 1996-03-07 Eli Lilly And Company Methods for identifying and treating resistant tumors
IL115582A0 (en) * 1994-10-14 1996-01-19 Lilly Co Eli Methods for treating resistant tumors
ZA961564B (en) * 1995-02-28 1997-08-27 Lilly Co Eli Methods of inhibiting ovarian cancer.
US5843974A (en) * 1995-06-06 1998-12-01 Eli Lilly And Company Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
CA2236543A1 (en) * 1995-11-07 1997-05-15 Alan David Palkowitz Methods for treating resistant tumors
ID15917A (id) * 1996-01-29 1997-08-21 Lilly Co Eli Metode untuk menghambat tumor usus besar
US5670523A (en) * 1996-01-29 1997-09-23 Eli Lilly And Company Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
AU707675B2 (en) * 1996-01-29 1999-07-15 Eli Lilly And Company Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
CZ300261B6 (cs) * 1996-10-30 2009-04-01 Eli Lilly And Company Použití hydrochloridové soli raloxifenu pro prípravu léciva pro prevenci rakoviny prsu
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
WO2002089801A1 (en) * 2001-05-10 2002-11-14 Cedars Sinai Medical Center Use of benzothiophenes to treat and prevent prostave cancer
US7425565B2 (en) 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
FR2873692B1 (fr) * 2004-07-29 2006-12-01 Univ Claude Bernard Lyon COMPOSITIONS CONTENANT, EN ASSOCIATION AVEC UN AGENT ANTIMICROBIEN, UN COMPOSE THIOPHENIQUE OU BENZOTHIOPHENIQUE DE FORMULE(I)PRESENTANT UNE ACTIVITE INHIBITRICE DE POMPE NorA

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes

Also Published As

Publication number Publication date
PT652004E (pt) 2002-10-31
HUT71237A (en) 1995-11-28
DE69430940T2 (de) 2003-04-03
ATE220323T1 (de) 2002-07-15
NO943874D0 (no) 1994-10-13
NO943874L (no) 1995-04-18
ZA948025B (en) 1996-04-15
JPH07149638A (ja) 1995-06-13
EP0652004B1 (en) 2002-07-10
HU9402961D0 (en) 1995-02-28
RU94037233A (ru) 1996-08-27
CZ253694A3 (en) 1995-05-17
ES2179063T3 (es) 2003-01-16
EP0652004A1 (en) 1995-05-10
AU7578694A (en) 1995-05-04
CN1108094A (zh) 1995-09-13
DE69430940D1 (de) 2002-08-14
KR950010891A (ko) 1995-05-15
CA2118096A1 (en) 1995-04-16
AU670518B2 (en) 1996-07-18
DK0652004T3 (da) 2002-09-02

Similar Documents

Publication Publication Date Title
IL112048A0 (en) Methods of inhibiting thrombin
SI0652005T1 (en) Methods for inhibiting endometriosis
HU9402960D0 (en) Methods of inhibiting uterine fibrosis
HU9402961D0 (en) Methods for treating resistant neoplasms
ZA9410086B (en) Methods of inhibiting seborrhea and acne
HU9402957D0 (en) Methods for inhibiting cartilage degradation